-+ 0.00%
-+ 0.00%
-+ 0.00%

Arvinas To Present Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Data For ARV-102 LRRK2 Degrader In Parkinson's Disease At AD/PD 2026

Benzinga·03/11/2026 11:14:22
Listen to the news

Presentation Title: Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ARV-102, a PROTAC LRRK2 Degrader, in Participants with Parkinson's Disease

Session Title: Modulating Neuroinflammation, Α-Synuclein, LRRK2, and Dopaminergic Repair: Early Human Data

Session Type: Symposium

Session Location: Hall 180-181 

Date: March 18, 2026

Lecture Time: 3:30-3:45 PM CET